Abstract
The myelodysplastic syndromes (MDS) are heterogeneous clonal disorders of ineffective hematopoiesis characterized by limited treatment options and a poor prognosis. These poor clinical characteristics stem from a poor understanding of the molecular abnormalities that drive disease pathogenesis. MicroRNAs (miRNAs) have recently been described to play wide-ranging roles in normal and malignant hematopoiesis, but very few miRNAs have been shown to be consistently dysregulated in MDS. Even fewer candidate disease miRNAs have undergone functional validation, and the clinical relevance of these miRNAs remains to be determined. Despite the fact that MDS has been shown to be a disease initiated in hematopoietic stem cells (HSC), most existing studies examining miRNA expression in MDS have used unfractionated or only partially purified bone marrow (BM) cell populations, likely explaining in part the limited insight that provided by these studies. A more robust characterization of purified disease -initiating cell populations followed by rigorous functional validation using in vivo disease models will be vital to identifying dysregulated miRNAs of functional significance in MDS. Such studies promise to provide key insights into disease pathogenesis and potentially open new avenues towards the development of therapies targeting miRNAs themselves or the pathways that they regulate.
Keywords: Bone marrow failure, hematopoietic stem cell, malignant hematopoiesis, microRNA, myelodysplasia, the myelodysplastic syndromes.
MicroRNA
Title:MicroRNA Dysregulation in the Myelodysplastic Syndromes
Volume: 2 Issue: 3
Author(s): Stephen S. Chung and Christopher Y. Park
Affiliation:
Keywords: Bone marrow failure, hematopoietic stem cell, malignant hematopoiesis, microRNA, myelodysplasia, the myelodysplastic syndromes.
Abstract: The myelodysplastic syndromes (MDS) are heterogeneous clonal disorders of ineffective hematopoiesis characterized by limited treatment options and a poor prognosis. These poor clinical characteristics stem from a poor understanding of the molecular abnormalities that drive disease pathogenesis. MicroRNAs (miRNAs) have recently been described to play wide-ranging roles in normal and malignant hematopoiesis, but very few miRNAs have been shown to be consistently dysregulated in MDS. Even fewer candidate disease miRNAs have undergone functional validation, and the clinical relevance of these miRNAs remains to be determined. Despite the fact that MDS has been shown to be a disease initiated in hematopoietic stem cells (HSC), most existing studies examining miRNA expression in MDS have used unfractionated or only partially purified bone marrow (BM) cell populations, likely explaining in part the limited insight that provided by these studies. A more robust characterization of purified disease -initiating cell populations followed by rigorous functional validation using in vivo disease models will be vital to identifying dysregulated miRNAs of functional significance in MDS. Such studies promise to provide key insights into disease pathogenesis and potentially open new avenues towards the development of therapies targeting miRNAs themselves or the pathways that they regulate.
Export Options
About this article
Cite this article as:
Chung S. Stephen and Park Y. Christopher, MicroRNA Dysregulation in the Myelodysplastic Syndromes, MicroRNA 2013; 2 (3) . https://dx.doi.org/10.2174/2211536602666131126002621
DOI https://dx.doi.org/10.2174/2211536602666131126002621 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
Call for Papers in Thematic Issues
Modulatory Roles of Non-coding RNAs in cancer therapy
This thematic issue aims to elucidate the most recent research on ncRNAs in CRCs and discuss the importance and difficulties that may arise in applying this tool on a regular clinical basis.read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Contemporary Progress in the Synthetic Strategies of Imidazole and its Biological Activities
Current Organic Synthesis Prospects for Hypoxia-Activated Anticancer Drugs
Current Medicinal Chemistry - Anti-Cancer Agents 3-Substituted-3-hydroxy-2-oxindole, an Emerging New Scaffold for Drug Discovery with Potential Anti-Cancer and other Biological Activities
Current Bioactive Compounds Pharmacogenetics of Non-small Cell Lung Cancer (NSCLC): Time to "Work it Out"?
Current Pharmaceutical Design The Clinical Significance of Incidental Parotid Uptake in a PET/CT Study: A Diagnostic Algorithm
Current Medical Imaging Deep Penetration of Nanoparticulate Drug Delivery Systems into Tumors: Challenges and Solutions
Current Medicinal Chemistry Green Synthesis of Zinc Oxide Nanoparticles (ZnO NPs) using Aqueous Extract of <i>Tagetes Erecta</i> flower and Evaluation of its Antioxidant, Antimicrobial, and Cytotoxic activities on HeLa cell line.
Current Biotechnology P-glycoprotein and Vacuolar ATPase Synergistically Confer Anthracycline Resistance to Fission Yeast and Human Cells
Current Medicinal Chemistry Subject Index To Volume 13
Protein & Peptide Letters Pharmacological Modulation of Sphingolipids and Role in Disease and Cancer Cell Biology
Mini-Reviews in Medicinal Chemistry Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Human Saliva Metabolome for Oral Lichen Planus Biomarker Identification
Recent Patents on Anti-Cancer Drug Discovery Strategies for Development of Antimalarials Based on Encapsulated Porphyrin Derivatives
Mini-Reviews in Medicinal Chemistry Melatonin Differentially Modulates NF-кB Expression in Breast and Liver Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Cytotoxicity and Molecular Targeting Study of Novel 2-Chloro-3- substituted Quinoline Derivatives as Antitumor Agents
Letters in Drug Design & Discovery Cytochrome P450 2W1 (CYP2W1) in Colorectal Cancers
Current Cancer Drug Targets Methylation of ZNF331 Promotes Cell Invasion and Migration in Human Esophageal Cancer
Current Protein & Peptide Science Thymidine Phosphorylase Over-Expression in Oral Squamous Carcinoma Tissue as a Potential Target of Capecitabine
Letters in Drug Design & Discovery MicroRNA-183 Functions As an Oncogene by Regulating PDCD4 in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets